Patent number for Microfluidic Valve Mechanism received

NewsGuard 100/100 Score

Microfluidic Systems, a privately-held company, announced today that they received patent number 7,607,641, entitled "Microfluidic Valve Mechanism". This patent covers a broad set of claims regarding the integration of a diaphragm membrane into a rigid body of a cartridge functioning as both a fluidic seal and cover of the cartridge, and as a valve mechanism for fluidics control within the cartridge. Diaphragm or membrane valves are a ubiquitous part of fluidic control devices and systems across a huge variety of applications. Diaphragm valves, for example, are typically used as shut-off valves in process systems for food and beverage, pharmaceutical, and biotech industries. Commonly, the module containing such a valve has a multitude of separate parts to seal the fluids and to provide the valve mechanism. This recently issued patent provides for an extremely simple to build, yet highly effective way to produce microfluidic cartridges or devices for these and other applications.

"This fundamental patent provides MFSI with a cost-effective way to produce precise microfluidic cartridges for applications in biological detection ranging from biodefense to clinical diagnostics." Dr. M. Allen Northrup, MFSI President and CEO said. "This particular patent continues to build our repertoire of microfluidic solutions to real-world, complex biological processing and analysis products," he added.

SOURCE Microfluidic Systems

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The role of glucose in inducing tolerance to amphotericin B for fungal meningitis treatment